AURKAIP1 Actuates Tumor Progression Through Stabilizing DDX5 in Triple Negative Breast Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2023 Dec 1

PMID 38040691

Authors

Wenwen Tian

Yuhui Tang

Yongzhou Luo

Jindong Xie

Shaoquan Zheng

Yutian Zou

Xiaojia Huang

Linyu Wu

Junsheng Zhang

Yuying Sun

Hailin Tang

Wei Du

Xing Li

Xiaoming Xie

Affiliations

Soon will be listed here.

Abstract

Aurora-A kinase interacting protein 1 (AURKAIP1) has been proved to take an intermediary role in cancer by functioning as a negative regulator of Aurora-A kinase. However, it remains unclear whether and how AURKAIP1 itself would directly engage in regulating malignancies. The expression levels of AURKAIP1 were detected in triple negative breast cancer (TNBC) by immunohistochemistry and western blots. The CCK8, colony formation assays and nude mouse model were conducted to determine cell proliferation whereas transwell and wound healing assays were performed to observe cell migration. The interaction of AURKAIP1 and DEAD-box helicase 5 (DDX5) were verified through co-immunoprecipitation and successively western blots. From the results, we found that AURKAIP1 was explicitly upregulated in TNBC, which was positively associated with tumor size, lymph node metastases, pathological stage and unfavorable prognosis. AURKAIP1 silencing markedly inhibited TNBC cell proliferation and migration in vitro and in vivo. AURKAIP1 directly interacted with and stabilized DDX5 protein by preventing ubiquitination and degradation, and DDX5 overexpression successfully reversed proliferation inhibition induced by knockdown of AURKAIP1. Consequently, AURKAIP1 silencing suppressed the activity of Wnt/β-catenin signaling in a DDX5-dependent manner. Our study may primarily disclose the molecular mechanism by which AURKAIP1/DDX5/β-catenin axis modulated TNBC progression, indicating that AURKAIP1 might serve as a therapeutic target as well as a TNBC-specific biomarker for prognosis.

Citing Articles

Jianpi Yangzheng Xiaozheng granule induced ferroptosis to suppress gastric cancer progression through reprogramming lipid metabolism via SCD1/Wnt/β-catenin axis.

Wang X, Li J, Qin R, Yin Y, Li J, Lin S Front Mol Biosci. 2025; 12:1523494.

PMID: 40070686 PMC: 11893430. DOI: 10.3389/fmolb.2025.1523494.

SLC35A2 is a novel prognostic biomarker and promotes cell proliferation and metastasis via Wnt/β-catenin/EMT signaling pathway in breast cancer.

Yan R, Chen T Sci Rep. 2025; 15(1):130.

PMID: 39748019 PMC: 11695858. DOI: 10.1038/s41598-024-84584-w.

TRAIP enhances progression of tongue squamous cell carcinoma through EMT and Wnt/β-catenin signaling by interacting with DDX39A.

Liu L, Wang P, Guo C, Song L, Chen L, Qi H BMC Cancer. 2024; 24(1):1481.

PMID: 39623306 PMC: 11610093. DOI: 10.1186/s12885-024-13130-8.

Circular RNA IGF1R Promotes Cardiac Repair via Activating β-Catenin Signaling by Interacting with DDX5 in Mice after Ischemic Insults.

Shan T, Yang T, Jing P, Bao Y, Zhou L, Zhu T Research (Wash D C). 2024; 7:0451.

PMID: 39193132 PMC: 11347128. DOI: 10.34133/research.0451.

Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple-Negative Breast Cancer.

Tian W, Zhu L, Luo Y, Tang Y, Tan Q, Zou Y Adv Sci (Weinh). 2024; 11(36):e2309903.

PMID: 39073262 PMC: 11423137. DOI: 10.1002/advs.202309903.

References

Teuliere J, Faraldo M, Deugnier M, Shtutman M, Ben-Zeev A, Thiery J . Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development. 2004; 132(2):267-77. DOI: 10.1242/dev.01583. View

Hwang S, Park S, Kwon Y . Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019; 199:30-57. DOI: 10.1016/j.pharmthera.2019.02.006. View

Bates G, Nicol S, Wilson B, Jacobs A, Bourdon J, Wardrop J . The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J. 2005; 24(3):543-53. PMC: 548656. DOI: 10.1038/sj.emboj.7600550. View

Xing L, Tang X, Wu K, Huang X, Yi Y, Huan J . TRIM27 Functions as a Novel Oncogene in Non-Triple-Negative Breast Cancer by Blocking Cellular Senescence through p21 Ubiquitination. Mol Ther Nucleic Acids. 2020; 22:910-923. PMC: 7666371. DOI: 10.1016/j.omtn.2020.10.012. View

Criscitiello C, Azim Jr H, Schouten P, Linn S, Sotiriou C . Understanding the biology of triple-negative breast cancer. Ann Oncol. 2012; 23 Suppl 6:vi13-8. DOI: 10.1093/annonc/mds188. View

Fabbri F, Salvi S, Bravaccini S . Know your enemy: Genetics, aging, exposomic and inflammation in the war against triple negative breast cancer. Semin Cancer Biol. 2019; 60:285-293. DOI: 10.1016/j.semcancer.2019.10.015. View

Chen H, Pan H, Qian Y, Zhou W, Liu X . MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. Mol Cancer. 2018; 17(1):4. PMC: 5759260. DOI: 10.1186/s12943-017-0754-0. View

Du R, Huang C, Liu K, Li X, Dong Z . Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. Mol Cancer. 2021; 20(1):15. PMC: 7809767. DOI: 10.1186/s12943-020-01305-3. View

Vasudevan S, Adejumobi I, Alkhatib H, Roy Chowdhury S, Stefansky S, Rubinstein A . Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures. Cancers (Basel). 2021; 13(19). PMC: 8507629. DOI: 10.3390/cancers13195009. View

10.

Liu Y, Xu J, Choi H, Han C, Fang Y, Li Y . Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. Nat Commun. 2018; 9(1):4718. PMC: 6226492. DOI: 10.1038/s41467-018-07264-0. View

11.

Agnese V, Bazan V, Fiorentino F, Fanale D, Badalamenti G, Colucci G . The role of Aurora-A inhibitors in cancer therapy. Ann Oncol. 2007; 18 Suppl 6:vi47-52. DOI: 10.1093/annonc/mdm224. View

12.

Hashemi V, Masjedi A, Hazhir-Karzar B, Tanomand A, Sandoghchian Shotorbani S, Hojjat-Farsangi M . The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer. J Cell Physiol. 2018; 234(5):5478-5487. DOI: 10.1002/jcp.26912. View

13.

Jacobs A, Nicol S, Hislop R, Jaffray E, Hay R, Fuller-Pace F . SUMO modification of the DEAD box protein p68 modulates its transcriptional activity and promotes its interaction with HDAC1. Oncogene. 2007; 26(40):5866-76. DOI: 10.1038/sj.onc.1210387. View

14.

Wang D, Huang J, Hu Z . RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. Mol Cell Proteomics. 2011; 11(2):M111.011932. PMC: 3277758. DOI: 10.1074/mcp.M111.011932. View

15.

Lim S, Gopalan G . Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A. Oncogene. 2007; 26(46):6593-603. DOI: 10.1038/sj.onc.1210482. View

16.

Man Y, Mannion C, Stojadinovic A, Peoples G, Cho W, Fu S . The most likely but largely ignored triggering factor for breast (or all) cancer invasion. J Cancer. 2023; 14(4):573-590. PMC: 10088539. DOI: 10.7150/jca.82291. View

17.

Malladi S, Macalinao D, Jin X, He L, Basnet H, Zou Y . Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 2016; 165(1):45-60. PMC: 4808520. DOI: 10.1016/j.cell.2016.02.025. View

18.

Ye F, Dewanjee S, Li Y, Jha N, Chen Z, Kumar A . Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023; 22(1):105. PMC: 10324146. DOI: 10.1186/s12943-023-01805-y. View

19.

Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G . Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020; 6:54. PMC: 7568552. DOI: 10.1038/s41523-020-00197-2. View

20.

Nyamao R, Wu J, Yu L, Xiao X, Zhang F . Roles of DDX5 in the tumorigenesis, proliferation, differentiation, metastasis and pathway regulation of human malignancies. Biochim Biophys Acta Rev Cancer. 2018; 1871(1):85-98. DOI: 10.1016/j.bbcan.2018.11.003. View